Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
NCT ID: NCT02909712
Last Updated: 2021-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
201 participants
INTERVENTIONAL
2016-09-30
2020-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
NCT02605720
Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa
NCT03208179
Improving Maternal heAlth by Reducing Malaria in African HIV Women
NCT03671109
Intermittent Preventive Treatment With Dihydroartemisinin-piperaquine in Papua, Indonesia
NCT05294406
Sulfadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine for Intermittent Preventive Treatment in Pregnancy
NCT05426434
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The QT interval, measured in milliseconds (MS) will be corrected (QTc) to account for natural heart rate (HR) extremes. The Fridericia formula will also be used to correct (QTcF) for variation in cardio-contraction. As part of the electrocardiogram (ECG), the period from the beginning of the P wave to the beginning of the QRS complex (PR interval) will be measured, as well as the ST-segment which connects the QRS complex and the T wave.
Prolongation of the QT interval will be estimated when peak drug-concentrations are most likely to be found in the peripheral blood as measured using pharmacokinetic (PK) techniques. Polymerase chain reaction (PCR) methods will be used for genetic sequencing of molecular markers (A581G) associated with malaria parasite drug resistance to SP. The rapid diagnostic test (RDT) CareStart™ will be used to screen pregnant women attending antenatal care.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sulfadoxine-pyrimethamine (SP)
* Group 1 (50 CareStart™ RDT-positive women)
* Group 2 (50 CareStart™ RDT-negative women)
These 100 women will have an ECG exam, provide blood for microscopy and molecular analysis, and receive SP on day 0. On days 7, 14, 21, and 28 women will provide blood for microscopy and molecular analysis.
sulfadoxine-pyrimethamine (SP)
Women in Groups 1 and 2 will be provided the following SP regimen as directly observed therapy:
3 tablets total of 500 mg sulphadoxine and 25 mg pyrimethamine; 1 day of dosing.
dihydroartemisinin-piperaquine (DHA-PQP)
* Group 3 (50 CareStart™ RDT-positive women)
* Group 4 (50 CareStart™ RDT-negative women)
These 100 women will have an ECG exam, provide blood for microscopy, molecular, and PK analysis, and receive DHA-PQP day 0. On day 1, women will receive dose 2. On day 2, women will have an ECG exam, begin Holter monitoring, provide blood for PK analysis, and receive dose 3. Blood for PK analysis will be drawn at 4, 5, and 6 hours following dose 3. An ECG exam will be conducted during this period and, again, on day 7. On days 7, 14, 21, and 28, women will provide blood for microscopy and molecular analysis.
dihydroartemisinin-piperaquine (DHA-PQP)
Women in Groups 3 and 4 will be provided the following DHA-PQP regimen as directly observed therapy 3 tablets of 40 mg dihydroartemisinin and 320 mg piperaquine daily; 9 tablets total; 3 days of dosing.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sulfadoxine-pyrimethamine (SP)
Women in Groups 1 and 2 will be provided the following SP regimen as directly observed therapy:
3 tablets total of 500 mg sulphadoxine and 25 mg pyrimethamine; 1 day of dosing.
dihydroartemisinin-piperaquine (DHA-PQP)
Women in Groups 3 and 4 will be provided the following DHA-PQP regimen as directly observed therapy 3 tablets of 40 mg dihydroartemisinin and 320 mg piperaquine daily; 9 tablets total; 3 days of dosing.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participant is between 18 years and 34 years of age.
3. Participant currently lives within the pre-defined catchment area of the district hospital.
4. Participant will remain within the same area through to the post-partum visit.
5. Participant agrees to deliver her child at the district hospital.
6. Participant agrees to a post-partum visit at her residence or at the district hospital.
7. Participant has no apparent severe infection or any condition that requires hospitalization.
8. Participant is not currently enrolled in another study.
9. Participant is not known to have heart disease or a known cardiac ailment.
10. Participant reports having taken no medication in the previous 28 days.
11. Participant reports having no known allergy to the study drugs or any sulphonamides.
12. Participant agrees to remain under observation for 3 hours at the district hospital and to abstain from food ingestion during the observation period in keeping with the European Medicines Agency product information for dosing with dihydroartemisinin-piperaquine.
13. Participant is willing to undergo all study procedures including sonography, ECG testing, and to provide blood samples for malaria microscopy and pharmacokinetic analysis.
14. Participant agrees to human immunodeficiency virus (HIV) testing regardless of prior results and no matter how recent.
15. Participant is not severely anaemic (haemoglobin concentration \> 5g/dL).
16. Participant provides written consent.
17. Participant has an axillary temperature \< 37.5 Celsius.
18. Participant is pregnant with a singleton determined by sonography.
19. Participant is between 16 and 35 weeks gestation determined by sonography.
Exclusion Criteria
2. Participant does not currently live within the pre-defined catchment area of district hospital.
3. Participant will not remain within the same area through to the post-partum visit.
4. Participant does not agree to deliver her child at the district hospital.
5. Participant does not agree to a post-partum visit at her residence or at the district hospital.
6. Participant has a severe infection or any condition that requires hospitalization.
7. Participant is currently enrolled in another study.
8. Participant is known to have heart disease or known cardiac ailment.
9. Participant reports having taken any medication in the previous 28 days.
10. Participant reports having an allergy to the study drugs or any sulphonamides.
11. Participant does not agree to abstain from food ingestion during the observation period after dosing.
12. Participant does not agree to remain under observation at the district hospital 3 hours after dosing has occurred.
13. Participant does not agree or is unwilling to undergo all study procedures including sonography, ECG testing, and to provide blood samples for malaria microscopy (and treatment group assignment) and pharmacokinetic analysis.
14. Participant does not agree to HIV testing or is diagnosed as HIV-positive during screening,
15. Participant is not severely anaemic (haemoglobin concentration \> 5g/dL).
16. Participant does not provide written consent.
17. Participant has an axillary temperature \> 37.5 Celsius or is symptomatic for malaria.
18. Participant is carrying a multiple pregnancy (e.g. twins).
19. Participant is between \< 16 weeks and \> 36 weeks gestation.
20. Participant has a QTc \> 450 milliseconds.
21. Participant has a heart rate \< 40 beats per minute.
18 Years
34 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kilimanjaro Christian Medical Centre, Tanzania
OTHER
National Institute for Medical Research, Tanzania
OTHER_GOV
London School of Hygiene and Tropical Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
R. Matthew Chico, MPH, PhD
Role: PRINCIPAL_INVESTIGATOR
London School of Hygiene and Tropical Medicine
Jacklin Mosha, MBBS, MSc, PhD
Role: PRINCIPAL_INVESTIGATOR
Kilimanjaro Christian Medical College
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Handeni District Hospital
Handeni, Tanga, Tanzania
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Food and Drug Administration, HHS. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist. 2005 Oct 20;70(202):61134-5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ITDCZF16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.